---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-006492"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:13:37.034083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NCCN guidelines updated to recommend PEDMARK for reducing cisplatin-induced hearing loss in pediatric AYA patients.

## Summary
- NCCN AYA Oncology guidelines now recommend PEDMARK to reduce cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors.
- PEDMARK, FDA-approved Sept 2022 and commercially launched Oct 2022, is first and only therapy for this indication.
- Hearing loss occurs in ~60% (up to 90%) of children treated with cisplatin; PEDMARK may reduce risk based on Phase 3 trials.
- FDA labeling states PEDMARK is not substitutable with other sodium thiosulfate products.

## SEC filing metadata
- accession: 0001104659-23-006492
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465923006492/0001104659-23-006492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465923006492/tm234393d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-006492
- JSON: https://secwatch.observer/filing/0001104659-23-006492.json
- Plain text: https://secwatch.observer/filing/0001104659-23-006492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.